• PP2A-Mediated Autophagy Modulates Drug Resistance in C. albi

  2026-04-20

  This study reveals that protein phosphatase 2A (PP2A) regulates autophagy via ATG protein phosphorylation, influencing both biofilm formation and antifungal drug resistance in Candida albicans. The findings highlight a key mechanism that may be targeted to improve antifungal therapy, with direct implications for resistance management in clinical and research settings.

• JNK-IN-7: Advancing Translational Strategies for JNK Pathway

  2026-04-19

  This thought-leadership article, authored by APExBIO's head of scientific marketing, explores the mechanistic and translational potential of JNK-IN-7—a selective JNK inhibitor—within infection-driven apoptosis and immune signaling research. Integrating foundational findings from recent peer-reviewed studies, it delivers strategic guidance for researchers aiming to harness JNK-IN-7 in dissecting MAPK pathways, apoptosis assays, and innate immune signaling modulation, with a special emphasis on its application in complex infection models, such as those involving Candida krusei. The article also benchmarks JNK-IN-7 against current landscape offerings, details protocol parameters, and provides a forward-looking perspective on emerging opportunities and limitations.

• Sabutoclax: Pan-Bcl-2 Inhibitor for Powerful Apoptosis Assay

  2026-04-18

  Sabutoclax delivers robust, reproducible apoptosis induction by targeting multiple Bcl-2 family proteins, making it a benchmark tool for cancer cell death studies. Its superior cell permeability, selectivity, and quantitative efficacy enable streamlined workflows and higher assay fidelity over legacy Bcl-2 inhibitors.

• BMS-777607: Advanced Paradigms in c-Met Inhibition for Cance

  2026-04-17

  Explore how BMS-777607, a potent c-Met inhibitor, is transforming both cancer metastasis models and hiPSC-derived platelet manufacturing. This article uniquely integrates mechanistic insights and protocol optimization for translational research.

• Bortezomib (PS-341): Reliable Workflows for Cellular Assays

  2026-04-16

  This article distills scenario-driven guidance for researchers leveraging Bortezomib (PS-341), SKU A2614, in cell viability and apoptosis assays. Drawing on validated literature and best practices, it addresses common laboratory challenges and highlights how Bortezomib (PS-341) ensures reproducibility, sensitivity, and workflow efficiency.

• Vemurafenib (PLX4032): Practical Workflows in Melanoma Resea

  2026-04-15

  Vemurafenib (PLX4032) is a benchmark BRAF V600E inhibitor for dissecting melanoma cell proliferation, resistance, and MAPK pathway rewiring. This article translates advanced multi-omics findings into actionable protocols, troubleshooting strategies, and comparative insights for researchers aiming to optimize cancer biology workflows.

• PINK1/Park2-Mediated Mitophagy Alleviates NAFLD: Mechanistic

  2026-04-14

  This study elucidates the protective role of PINK1/Park2-mediated mitophagy in non-alcoholic fatty liver disease (NAFLD), demonstrating that modulating Park2 expression can reverse mitochondrial and hepatic damage. The findings highlight mitophagy as a promising therapeutic target for NAFLD and provide a framework for future studies on mitochondrial quality control.

• 5-Azacytidine Induces ATR-Mediated DNA Damage in Myeloma Cel

  2026-04-13

  This study demonstrates that 5-azacytidine, a DNA methyltransferase inhibitor, triggers ATR-mediated DNA double-strand break responses and apoptosis in multiple myeloma cells, including drug-resistant variants. The findings reveal synergistic cytotoxicity when combined with doxorubicin or bortezomib, supporting further investigation of such combinations for therapy-resistant multiple myeloma.

• Methyl-β-cyclodextrin: Technical Guide for Membrane Studies

  2026-04-12

  Methyl-β-cyclodextrin (SKU C6939) is a high-purity reagent for extracting cholesterol and modulating membrane lipid organization in cell-based and biochemical workflows. It is not intended for diagnostic or medical use. This article details practical setup, protocol parameters, and troubleshooting for research applications.

• GSK621: Precision AMPK Agonist for Advanced Metabolic Resear

  2026-04-12

  GSK621 stands out as a potent AMPK agonist enabling high-fidelity metabolic reprogramming in immunometabolic and acute myeloid leukemia (AML) models. This article delivers actionable guidance on experimental workflows, troubleshooting, and protocol optimization, directly bridging novel mechanistic insights from recent landmark studies to practical laboratory application.

• L-Alanyl-L-Glutamine: Protocol-Driven Advances in Intestinal

  2026-04-11

  L-Alanyl-L-glutamine empowers gastrointestinal research with superior stability and targeted mucosa protection—outperforming traditional glutamine sources for barrier assays. This article unpacks optimized protocols, troubleshooting strategies, and translational insights, clarifying why APExBIO’s dipeptide is the new standard for gut barrier and inflammation research.

• Cy3 NHS ester (non-sulfonated): Technical Guide for Protein,

  2026-04-11

  Cy3 NHS ester (non-sulfonated) enables precise fluorescent labeling of proteins, peptides, and oligonucleotides via amino group conjugation, supporting sensitive detection in imaging and analytical workflows. It is best used when aqueous solubility is not required, and organic co-solvents are acceptable. Avoid use with delicate proteins that are incompatible with DMSO or DMF.

• FerroOrange: Precision Fe²⁺ Indicator for Live Cell Iron ...

  2026-04-10

  FerroOrange is a validated Fe²⁺ fluorescent probe designed for robust, live cell ferrous ion detection. This product dossier details its mechanistic specificity, benchmarks in iron metabolism research, and workflow integration for fluorescence microscopy and flow cytometry applications.

• Harnessing Latrunculin A for Translational Cytoskeleton R...

  2026-04-09

  Explore how Latrunculin A, a potent reversible inhibitor of actin assembly, is redefining cytoskeleton dynamics research and translational strategies in cell biology and oncology. This thought-leadership article integrates mechanistic insights, competitive analysis, and actionable guidance for leveraging actin cytoskeleton disruption in advanced research, while contextualizing Latrunculin A’s unique value for dissecting actin–myosin II networks in the context of viral pathogenesis and tumor cell migration.

• TAK-715: Selective p38α MAPK Inhibitor for Inflammation R...

  2026-04-08

  TAK-715 stands out as a potent, highly selective p38 MAPK inhibitor, streamlining cytokine signaling and inflammation research workflows. Its nanomolar potency, dual-action mechanism, and proven efficacy in cellular and in vivo models empower researchers to achieve reproducible, high-impact results in chronic inflammatory disease studies.

451 records 21/31 page Previous Next First page 上5页 2122232425 下5页 Last page